Form 4: Quoin Pharmaceuticals Director Acquires Shares and Warrants in Public Offering

Director Anthony James Culverwell purchased 100,000 ordinary shares and warrants in Quoin Pharmaceuticals' public offering at $0.45 per share.

Summary

• Anthony James Culverwell, a director of Quoin Pharmaceuticals, acquired 100,000 ordinary shares and warrants in the company's public offering.
• The transaction occurred on December 23, 2024.
• The purchase price was $0.45 per share.
• Culverwell now beneficially owns 100,317 ordinary shares.
• He also acquired Series F and Series G warrants, each for 100,000 ADSs (American Depositary Shares).
• Each ADS represents one ordinary share of Quoin Pharmaceuticals.
• The Series F warrants are exercisable immediately and expire on December 23, 2026.
• The Series G warrants are exercisable immediately and expire on December 24, 2029.
• The warrants were acquired as part of a unit in the public offering, with each unit consisting of one ADS, one Series F warrant, and one Series G warrant.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports a transaction. The director's purchase is a mildly positive signal, but it's a routine filing.

Positives

• A director's purchase of shares and warrants can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements beyond the expiration dates of the warrants.

Industry Context

Form 4 filings are standard disclosures for insiders' transactions and provide transparency to the market.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Quoin Pharmaceuticals, Director, Culverwell, Share purchase, Warrants, Public offering, ADS, QNRX